A cutting-edge treatment for hair loss has been developed by Pelage Pharmaceuticals, a company at the forefront of regenerative medicine.

Ranok Therapeutics has commenced a Phase 1 clinical trial in China for RNK05047, its first protein degrader candidate.

Journey Medical Corporation announced positive results from their Phase 1 clinical trial of DFD-29, aimed at treating rosacea.

ImmunAbs has achieved milestone success by completing Phase 1 clinical trials for their new antibody therapeutic, IM-101.

FSD Pharma has submitted a Clinical Trial Application (CTA) for a Phase-1b study, the METAL-1 TRIAL, to evaluate the safety and efficacy of its dietary supplement, unbuzzd™.

Delta-Fly Pharma has recently completed the submission of a Phase I/II clinical trial protocol for a combination therapy involving their drug DFP-10917 and Venetoclax (VTX).

Syena, a subsidiary of Replay specializing in cell therapy, has initiated a Phase 1/2 clinical trial for patients with multiple myeloma.

Immuneering Corporation has commenced the Phase 2a segment of its Phase 1/2a clinical trial for IMM-1-104.

Plus Therapeutics has successfully dosed 18 patients in the ReSPECT-LM Phase 1 trial, which focuses on the treatment of leptomeningeal metastases (LM) from solid tumors using rhenium (186Re) obisbemeda.

The Data Safety Monitoring Board (DSMB) has reviewed the safety of SON-080 in the Phase 1b part of Sonnet's clinical trial.

Nurix Therapeutics has received a boost as the FDA lifted a partial clinical hold on their Phase 1a/1b study of NX-2127.

Synnovation Therapeutics has announced the commencement of dosing for the first patient in their Phase I clinical trial of SNV1521, a PARP1 inhibitor, in patients with solid tumors.